Replies to post #379544 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

powerwalker,

Donpezil (Aricept) is not listed in the inclusion or exclusion criteria for the Phase 2b/3 trial details at website clinical trials.gov

Therefore it does not appear that concomitent use of donepezil (Aricept) is allowed for this trial.

Since donepezil (Aricept) is a sigma-1 receptor ligand, it is thought that donepzil (Aricept) may be a competitor for binding to the sigma-1 receptor versus Blarcamesine, therefore may be a negative factor if used concomitantly with Blarcamesine.

Good luck and GOD bless,

[Investor2014]

No I don't think so and yes I have no doubt that co-administered psychoactive medications, such as Donepezil, will be part of the KEM subgroup analysis just as it was in the P2a study.

By what theory, other than a biased one, would Donepezil not better the earlier administrated in the AD disease progress?

The earlier the better seems to apply to A2-73. Early or prodromal treatment is a main thesis by most AD research.

Unsurprisingly this idea has been tested also for Donepezil: Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

Conclusion: These data suggest significant treatment benefits of donepezil in early-stage Alzheimer disease, supporting the initiation of therapy early in the disease course to improve daily cognitive functioning.